Viking Therapeutics (VKTX) Cash from Investing Activities (2015 - 2026)

Viking Therapeutics has reported Cash from Investing Activities for 12 years, with the latest figure at $109.4 million in Q2 2026.

• Quarterly Cash from Investing Activities rose 157.45% year-over-year to $109.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $399.3 million (up 188.82% YoY) and the FY2025 annual result came in at $341.4 million, up 161.69% from the prior year.
• Cash from Investing Activities rose to $109.4 million in Q2 2026 per VKTX's latest filing, from $54.2 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at $160.0 million in Q3 2025 and troughed at -$459.8 million in Q1 2024.
• A 5-year average of -$9.6 million and a median of $22.4 million in 2022 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities sank 21018.65% in 2024, then jumped 1048.42% in 2025.
• Over 5 years, Cash from Investing Activities stood at $7.3 million in 2022, then soared by 392.19% to $35.7 million in 2023, then plunged by 81.57% to $6.6 million in 2024, then surged by 1048.42% to $75.6 million in 2025, then soared by 44.73% to $109.4 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered $109.4 million, $54.2 million, and $75.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.